Multiple transgene recombinant adenovirus
US12036247B2 · kind B2 · utility
0Cited by
3References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 12, 2018 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Feb 15, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21075
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a recombinant adenovirus comprising two or more therapeutic transgenes, e.g., two components of a heterodimeric cytokine, separated by a cleavable linker.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.